Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 5/20 | 0.68 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.68 |
| ▸ | AR | P10275 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | HSD3B1 | P14060 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | THPO | P40225 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14506163 | 1.00 | SRD5A2 (0.68) | SRD5A2SRD5A1ARLMNACYP3A4 | |
| SCHEMBL5699698 | 1.00 | SRD5A2 (0.68) | SRD5A2SRD5A1ARLMNACYP3A4 | |
| SCHEMBL26155447 | 1.00 | SRD5A2 (0.68) | SRD5A2SRD5A1ARLMNACYP3A4 | |
| SCHEMBL4019990 | 1.00 | SRD5A2 (0.68) | SRD5A2SRD5A1ARLMNACYP3A4 | |
| SCHEMBL5699657 | 1.00 | SRD5A2 (0.68) | SRD5A2SRD5A1ARLMNACYP3A4 | |
| SCHEMBL9215708 | 0.92 | SRD5A2 (0.64) | SRD5A2SRD5A1ARLMNACYP3A4 | |
| SCHEMBL9215700 | 0.92 | SRD5A2 (0.64) | SRD5A2SRD5A1ARLMNACYP3A4 | |
| SCHEMBL9562169 | 0.91 | SRD5A2 (0.65) | SRD5A2SRD5A1ARLMNACYP3A4 | |
| SCHEMBL9562162 | 0.91 | SRD5A2 (0.65) | SRD5A2SRD5A1ARLMNACYP3A4 | |
| SCHEMBL10485635 | 0.91 | SRD5A2 (0.68) | SRD5A2SRD5A1ARLMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0298652-A2 | Dehydrogenation process and intermediates | MERCK & CO. INC. (US) | 1989-01-11 | — | — | EP | claimed |
| US-7531658-B2 | Reacting 17-carboxylic acid-3-oxo-4-azasteroid with carbonyl- or sulfinyl-diimidazole and amidating the product with an amime in the presence of a heterocyclic hydroxyl activator; avoids the use of expensive and moisture sensitive organomagnesium halide; preparing Finasteride and Dutasteride | APOTEX PHARMACHEM INC. (CA) | 2009-05-12 | — | — | US | disclosed |
| WO-2008101308-A1 | PROCESS FOR THE PREPARATION OF 17-N-SUBSTITUTED-CARBAMOYL-4-AZA-ANDROST-1 -EN-3-ONES | APOTEX PHARMACHEM INC. (CA) | 2008-08-28 | — | — | WO | disclosed |
| EP-1437361-B1 | METHOD OF PRODUCING 17BETA-(SUBSTITUTED)-3-OXO-DELTA 1,2-4-AZASTEROIDS | RAGACTIVES SL (ES) | 2007-10-31 | — | — | EP | disclosed |
| US-20070173523-A1 | Process for the preparation of 17-N-substituted-carbamoyl-4-aza-androst-1-en-3-ones | APOTEX PHARMACHEM INC. (CA) | 2007-07-26 | — | — | US | disclosed |
| EP-1504021-B1 | PROCESS FOR DEHYDROGENATION OF AZAANDROSTANE COMPOUNDS | RICHTER GEDEON VEGYESZET (HU) | 2006-07-12 | — | — | EP | disclosed |
| US-7057045-B2 | Process for obtaining 17β-(substituted)-3-oxo-Δ1,2-4-azasteroids and intermediates | RAGACTIVES, S.L. (ES) | 2006-06-06 | — | — | US | disclosed |
| US-7038050-B2 | Method for the preparation of highly pure 1-androstene derivatives | HANMI PHARM. CO., LTD. (KR) | 2006-05-02 | — | — | US | disclosed |
| EP-1646640-A1 | METHOD FOR THE PREPARATION OF HIGHLY PURE 1-ANDROSTENE DERIVATIVES | Hanmi Pharm. Co., Ltd. (KR) | 2006-04-19 | — | — | EP | disclosed |
| US-20050245744-A1 | Method for the preparation of highly pure 1-androstene derivatives | HANMI PHARM. CO., LTLD. (KR) | 2005-11-03 | — | — | US | disclosed |
| EP-0285382-B1 | Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO INC (US) | 1994-04-13 | — | — | EP | disclosed |
| EP-0285383-B1 | Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO INC (US) | 1994-03-16 | — | — | EP | disclosed |
| EP-0547691-A1 | The use of 17B-N-mono-substituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones for the preparation of a medicament for the prevention of prostatic carcinoma | MERCK & CO. INC. (US) | 1993-06-23 | — | — | EP | disclosed |
| US-5116983-A | Azasteroids as intermediates | MERCK & CO., INC. (US) | 1992-05-26 | — | — | US | disclosed |
| US-5084574-A | Reacting a 3-oxo-4-azasteroid with a silyating agent and quinone to form a double bond at the #1 ring position | MERCK & CO., INC. (US) | 1992-01-28 | — | — | US | disclosed |
| EP-0298652-A2 | Dehydrogenation process and intermediates | MERCK & CO. INC. (US) | 1989-01-11 | — | — | EP | disclosed |
| EP-0285383-A2 | Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| EP-0285382-A2 | Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| US-4760071-A | Enzyme inhibitor | MERCK & CO., INC. (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0155096-A2 | 17 Beta-Substituted-4-aza-5-alpha-androstenones and their use as 5-alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1985-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245744-A1 | Method for the preparation of highly pure 1-androstene derivatives | CYP19A1, HSD17B11, CYP17A1 | SRD5A2 12/4885SRD5A1 18/4885AR 39/4885 |
| US-20070173523-A1 | Process for the preparation of 17-N-substituted-carbamoyl-4-aza-androst-1-en-3-ones | CYP17A1, CYP19A1, NR5A1 | SRD5A2 15/4885SRD5A1 16/4885AR 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.